权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Investigating cells of origin and oncogenic modifiers of 3q26-driven LUSC

研究 3q26 驱动的 LUSC 的起源细胞和致癌修饰因子

基本信息

批准号：
10593501
负责人：
Alan P. Fields
金额：
$ 7.37万
依托单位：
MAYO CLINIC JACKSONVILLE
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-07-01 至 2026-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10593501
关键词：
3q26 Accounting Alleles Alveolar Auranofin Biochemical Biogenesis Bioinformatics Biological Biological Markers Cancer Etiology Cells Cessation of life Chromosomes Clinical Combined Modality Therapy Data Diagnosis Drug Combinations Enterobacteria phage P1 Cre recombinase Event Exhibits Genes Genetic Genetic Recombination Genetic Transcription Genetic study Genetically Engineered Mouse Genomics Growth Histologic Human In Vitro Intervention Keratin Knock-in Knock-out Knowledge Lesion Lung Lung Adenocarcinoma Lung Neoplasms MEKs Malignant Epithelial Cell Malignant neoplasm of lung Modeling Molecular Profiling Morphology Mus Mutation Neoplasm Metastasis Non-Small-Cell Lung Carcinoma Oncogenes Oncogenic Outcome Pathway interactions Patients Pharmacology Phenotype Play Prognosis Property Proteins Recurrence Relapse Resources Ribosomal DNA Ribosomes Role Signal Transduction Signaling Protein Squamous Cell Lung Carcinoma Squamous cell carcinoma Structure of parenchyma of lung TP53 gene Testing Therapeutic Therapeutic Intervention Transgenes Tumor-Derived United States World Health Organization alveolar type II cell base biological heterogeneity cancer diagnosis cell growth cell transformation clinically relevant conditional knockout design druggable target early detection biomarkers genomic signature improved in vivo inhibitor insight mouse model neoplastic cell new therapeutic target notch protein novel novel therapeutic intervention overexpression parent grant pharmacodynamic biomarker pre-clinical predictive marker premalignant programs promoter recombinant adenovirus response self-renewal stem cells targeted treatment treatment response tumor tumor growth tumor heterogeneity tumor initiation tumor progression tumorigenesis

项目摘要

Project Abstract Lung squamous cell carcinoma (LUSC) is a major subtype of lung cancer accounting for ~30% of all lung cancer diagnoses. LUSC patients suffer from poor therapeutic response, high relapse rate, and poor prognosis. A major reason for this bleak outcome is a lack of well characterized oncogenic drivers of LUSC that can be targeted therapeutically. We have identified concomitant 3q26 copy number gain (CNG) and TP53 loss as defining genetic alterations present in ~90% of LUSC tumors.2 Furthermore, we have identified 3 3q26 oncogenes, PRKCI, ECT2 and SOX2, that genetically and biochemically collaborate to drive LUSC tumor formation.2-4 We have developed the first genetically engineered mouse model (GEMM) to study these genetic alterations in LUSC tumorigenesis in vivo.1 Our GEMM allows inducible overexpression of Prkci, Ect2, and Sox2 and knockout of Trp53 (PES/Trp53-/-) in lung tissue. Specific Aims of the parent grant are to: 1) evaluate the effect of pharmacologic inhibitors of PKCι (the protein product of PRKCI) and PKCι effector pathways on PES/Trp53-/--driven LUSC; and 2) characterize tumor initiation and progression in our PES/Trp53-/- LUSC GEMM from lung basal stem cells (LBSCs), a major cell of origin for LUSC. Interestingly, two other regional lung stem cells (Club and alveolar type II (AT2) cells) can also serve as cells of origin for LUSC.5-7 Moreover, we have identified additional genes within the recurrent 3q26 amplicon that may play promotive roles in PES/Trp53-/--driven LUSC. Based on these new observations, we hypothesize that: 1) PES/Trp53-/- mice can develop LUSC tumors from multiple cells of origin, giving rise to LUSC tumors with distinct biological, genomic and biochemical properties; and 2) additional genes within the 3q26 amplicon contribute to PES/Trp53-/--driven LUSC. These hypotheses will be tested through two interrelated specific aims designed to: 1) To assess the ability of PES/Trp53-/- mice to generate LUSC tumors from Club and AT2 cells in vivo; and 2) determine genomic and molecular signatures of PES/Trp53-/--driven LUSC tumors from distinct cells of origin. This supplement project is a significant extension of Aim 2 of the parent grant which proposes to characterize a novel GEMM of PES/Trp53-/--driven LUSC from LBSCs. The proposed studies will expand the parent grant by: 1) assessing the role of alternative cells of origin (Club and AT2 lung stem cells) in LUSC tumor formation; 2) identifying genomic and molecular signatures of LUSC tumors arising from LBSC, Club, and AT2 lung stem cells; and 3) characterizing the role of recently identified 3q26 genes as possible modifiers of LUSC tumorigenesis. Completion of these studies will provide novel insights into biological heterogeneity observed in LUSC tumors harboring 3q26 CNG and identify oncogenic signaling pathways and genes that may be useful as biomarkers of LUSC tumorigenesis and serve as targets for therapeutic intervention.

项目摘要肺鳞状细胞癌（LUSC）是肺癌的一种主要亚型，约占所有肺癌的30 癌症诊断LUSC患者的治疗反应差，复发率高，且不良反应少。预后这种暗淡结果的一个主要原因是缺乏LUSC的良好表征的致癌驱动因素可以作为治疗靶点。我们已经确定了伴随的3q 26拷贝数增加（CNG）， TP 53缺失作为定义遗传改变存在于~90%的LUSC肿瘤中。2此外，我们已经鉴定了3个 3q 26癌基因，PRKCI，ECT 2和SOX 2，在遗传和生物化学上协作驱动LUSC肿瘤 2 -4我们已经开发了第一个基因工程小鼠模型（GEMM）来研究这些基因。 1我们的GEMM允许Prkci、Ect 2和Ect 3的诱导性过表达。 Sox 2和Trp 53敲除（PES/Trp 53-/-）。父母补助金的具体目标是：1）评估 PKC i（PRKCI的蛋白质产物）和PKC i效应途径的药理学抑制剂对 PES/Trp 53-/-驱动的LUSC;和2）表征我们的PES/Trp 53-/- LUSC中的肿瘤起始和进展 GEMM来自肺基底干细胞（LBSC），LUSC的主要起源细胞。有趣的是，另外两个区域肺干细胞（Club和肺泡II型（AT 2）细胞）也可以作为LUSC的起源细胞。5 -7此外，我们已经鉴定了在复发性3q 26扩增子中的另外的基因，其可能在以下中起促进作用： PES/Trp 53-/-驱动的LUSC。基于这些新的观察，我们假设：1）PES/Trp 53-/-小鼠可以从多种来源的细胞发展LUSC肿瘤，产生具有不同生物学特性的LUSC肿瘤，基因组和生物化学性质;和2）3q 26扩增子内的其它基因有助于 PES/Trp 53-/-驱动的LUSC。这些假设将通过两个相互关联的具体目标进行测试， 1）评估PES/Trp 53-/-小鼠在体内从Club和AT 2细胞产生LUSC肿瘤的能力;和 2)确定来自不同细胞的PES/Trp 53-/-驱动的LUSC肿瘤的基因组和分子特征起源这一补充项目是母补助金目标2的重要延伸，该目标提出，表征来自LBSC的PES/Trp 53-/-驱动的LUSC的新型GEMM。拟议的研究将扩大父母资助：1）评估替代来源细胞（Club和AT 2肺干细胞）在LUSC中的作用肿瘤形成; 2）鉴定由LBSC，Club，和AT 2肺干细胞;和3）表征最近鉴定的3q 26基因作为可能的修饰剂的作用 LUSC肿瘤发生。这些研究的完成将为生物异质性提供新的见解在携带3q 26 CNG的LUSC肿瘤中观察到，并识别可能致癌的信号通路和基因可用作LUSC肿瘤发生的生物标志物并用作治疗干预的靶点。